Michael Rosenblatt, MD, Senior Partner at Flagship Pioneering, has advanced academic and biopharmaceutical research and development throughout his career. He was previously Chief Medical Officer for Merck, after serving as Dean of Tufts Medical School. Formerly, he was Ebert Professor of Molecular Medicine and Minot Professor at Harvard. He served as President of Beth Israel Deaconess Medical Center and as Director of the Harvard-MIT Division of Health Sciences & Technology. He is on the board of several life sciences companies, and on the Harvard Medical School Board of Fellows and research advisory committees of the Massachusetts General, Brigham and Women’s, and Boston Children’s Hospitals. He earned his MD from Harvard Medical School.

Dr. Verst is president, Design and Delivery Innovation, Research & Development Solutions at IQVIA. She is responsible for driving innovation and transformation throughout the trial lifecycle. Having previously served as president of both clinical operations and real world and late phase research for IQVIA, Dr. Verst brings a holistic and comprehensive view of clinical research, and champions the advanced use of real-world data, analytics and technology to advance therapies for patients. Recognized by Fierce Biotech as a top woman in biotech, and as a PharmaVoice 100 leader, she currently sits on the Board of Directors for the Association of Clinical Research Organizations and is the Chair of the DIA Board of Directors.

Dr. Takahashi is currently Partner at Mirasense Partners. He graduated from Hokkaido University School of Medicine and receiving his PhD in Medical Science in 1986. He served as VP, Merck Research Laboratories from 2003 to 2008. He joined LOTUS Pharmaceutical Co. Ltd, a bio-venture company in 2009, and served as a President & CEO before joining GSK, where he served as VP and Director of Japan Development until 2019. After retiring GSK, he served as Director and COO at BONAC Corporation, a bio-venture company, and then joined Mirasense Partners in 2020. He has been actively involved in industry activities including DIA, IFAPP, and EFPIA since he joined pharmaceutical industry. He is currently serving as a Councilor of JAPhMed.

Tatyana Kosheleva, CPA, is currently CFO at Amring Pharmaceuticals Inc. where she is a member of the Executive Board responsible for all aspects of the firm's financial operations. Tatyana has over 20 years of diverse Finance experience ranging from start-ups to Fortune 50 public companies in the life sciences and technology industries across four countries. Tatyana earned her MBA degree in International Management from Thunderbird School of Global Management, a part of the Arizona State University.

Junaid is the Chief Medical Scientist at Microsoft Research and a practicing physician in the UK’s National Health Service. Junaid has worked across primary care, secondary care, and public health settings in addition to acting as a payer, and policymaker within the UK, where he specialized in informatics, digital transformation, and leadership. He has consulted for health care systems across the US, Europe, Australia, the Middle East, Singapore, and Europe. Academically, he is a Clinical Associate Professor at UCL (University College London), and Visiting Scientist at the Harvard School of Public Health.

Prior to joining DIA in 2023, Fathallah was the Operating Officer and EVP at Ortho Clinical Diagnostics, accountable for Operations, Post Market Product Science and Engineering, Regulatory, Quality, Medical, Clinical, Scientific Affairs, and Process Excellence. Before joining Ortho, he held Executive and Senior Leadership roles in Research and Development, Operations, and Regulatory Medical and Clinical Affairs at Avantor, Danaher, Pfizer, Hospira, and Abbott Laboratories. Fathallah holds a Master’s and Bachelor of Science degrees in Mechanical Engineering from the Univ. of Wisconsin-Madison and an MBA from the Kellogg School of Management at Northwestern University.

Jens Grueger is a Director and Partner at the Boston Consulting Group based in Zurich, Switzerland. He joined BCG in 2019 as a senior expert for pricing and market access in healthcare and serves both industry and Global Health clients. He is also a Fellow at the BCG Henderson Institute, where his research focuses on systems solutions for equity and access to healthcare. Jens is an Affiliate Professor of Health Economics at the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington School of Pharmacy in Seattle, USA, and the 2020-2021 President of ISPOR, the leading professional society for health economics and outcomes research.

Dr. Honig is former SVP and Head of Global Regulatory Affairs and Group Head of Development for China and Japan, overseeing regulatory effectiveness, quality control and compliance at Pfizer. Prior to joining Pfizer, he held senior leadership positions at AstraZeneca, Merck Research Laboratories and the FDA, which includes being the first Director of the Office of Drug Safety in the FDA’s Center for Drug Evaluation and Research (CDER). In addition to his industry and FDA experience, Dr. Honig was the PhRMA representative to the ICH Steering Committee from 2002 to 2021 and is a past President of the American Society for Clinical Pharmacology and Therapeutics (ASCPT). Dr. Honig received his BA, MD, and MPH from Columbia University.

Dr. Jiang has over 30 years of experience in management of medical practice and pharmaceutical industry. Dr. Jiang is the Chief Strategy Officer and a Board Director at Hengrui (a global top 50 pharma), where he oversees corporate strategy, clinical development, and business development. Prior to Hengrui, Dr. Jiang served as the founding CEO and Chairman of the Board at CStone Pharmaceuticals, a leading biotech in China where Dr. Jiang led the team to build its pipeline from zero to 16 assets, including 4 marketed products with a total of 10 approved indications. Prior to CStone, Dr. Jiang was the Head of Asia Pacific R&D (including Japan) for Sanofi.

Jason joined Ancillare as President with over 25 years of experience in the healthcare, medical device, and life sciences industries. He most recently served as Chief Business and Strategy Officer at dMed-Clinipace, a global mid-sized Contract Research Organization (CRO), and Chief Executive Officer at Clinipace prior to its 2021 merger with dMed. In prior years, Jason founded Pivotal Financial Consulting, a consultancy where he advised investors and companies in the clinical research sector, focused on acquisitions, growth and innovation. Jason was also Chief Financial Officer and Executive Vice President for Theorem Clinical Research, a global mid-sized Contract Research Organization acquired by Chiltern International in 2015.

Palani is a seasoned C-suite global innovation executive with over 25 years of experience in the broad field of life sciences. In his tenure at GE Healthcare, Life Technologies, Terumo BCT, Epic Sciences and QuidelOrtho, he led the development of disruptive industry defining bench to bedside technologies for academia, pharma, biopharma, medical devices and clinical diagnostics segments. Palani has been an integral member of diversification and growth strategies in the associated firms. He is on the Board of multiple for-profit and non-profit entities within the life sciences industry. Palani has a PhD degree in the field of biomedical sciences from Northern Illinois University.

Peter is an accomplished drug developer and innovative senior pharmaceutical executive who advises boards, private equity investors, and leaders across the pharmaceutical and biotech industry. He has extensive global experience across a broad range of therapeutic areas, including oncology, immunology, neuroscience, vaccines, anti-infectives, cardiovascular and retinal gene therapy - from First in Human to Medical Affairs. Prior to joining Janssen in 2017, Peter was the SVP of Global Clinical Operations at BMS where he had spent 14 years holding positions of increasing leadership scope in Medical Affairs, Regulatory Operations and R&D Operations. He also served on the TransCelerate Biopharmaceutical Board of Directors.

Peter Sorger is the Otto Krayer Professor of Systems Pharmacology at Harvard Medical School. He received his AB from Harvard College and PhD from Trinity College, Cambridge University U.K., working under the supervision of Hugh Pelham. He trained as a postdoctoral fellow at the University of California, San Francisco with Harold Varmus and Andrew Murray. Prior to coming to HMS Peter served as a Professor of Biology and Biological Engineering at MIT. Sorger was cofounder of Merrimack Pharmaceuticals and Glencoe Software and is an advisor to multiple public and private companies and research institutes in the US, Europe and Japan.

Rachel has over two decades of healthcare consulting and life science management experiences. Formerly a partner in McKinsey & Company’s New York Office, Rachel oversaw the design and delivery of corporate and R&D transformation programs, working with leading pharmaceutical companies as well as global health non-profit organizations. In 2016 she founded New Path Global LLC, to strengthen collaboration across academia, industry, and funders, towards long-term patient and society benefits. Rachel started her career as a drug discovery biochemist with Merck Research Laboratories in West Point, Pennsylvania. She also obtained an MBA from The Wharton School

Craig is an executive leader with a strong, diverse background in finance, operations, and business development. 20 years of experience with both private and public emerging growth, life science companies, including 8+ years serving as CFO. Demonstrated success and significant business performance improvements across multiple corporate functions to drive financial performance through organic revenue growth, acquisitions, and operational efficiencies. Craig holds an active CPA license, has an undergraduate degree in Accounting from Saint Joseph’s University, and an Executive MBA degree from Villanova University.

Yan Xiaojun (Wendy Yan), MBA, is the Senior Vice President, Chief Regulatory Officer, leading the global regulatory affairs organization in BeiGene since 2014. Wendy has over 25 years of regulatory affairs and development experience. She has skillfully built the BeiGene global regulatory affairs team from scratch, which now comprises around 300 employees worldwide, including China, the US, EU, Japan, APAC, and new market, etc. While leading the global team in developing global regulatory strategies, Wendy and her team have successfully achieved NDAs approval in more than 60 markets worldwide.